EUCTR2015-001467-39-ES进行中（未招募）不适用
A phase II study to evaluate the safety and efficacy of lenvatinib in patients with advanced grade 1/2 neuroendocrine neoplasmas of pancreatic and extrapancreatic origin. - TALENT
GETNE (Grupo Español de Tumores Neuroendocrinos)0 个研究点目标入组 110 人开始时间: 2015年7月10日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Subjects must have histologically confirmed diagnosis of one of the following advanced/metastatic neuroendocrine tumor types:
- •a)WHO Classification G1/G2 (Ki67<20% and mitotic count ?20 mitoses x 10 HPF) pancreatic neuroendocrine tumor
- •b)WHO Classification G1/G2 (Ki67<20% and mitotic count ?20 mitoses x 10 HPF) gastrointestinal neuroendocrine tumor (including stomach, small intestine and colorectal origins).
- •2.Subjects must have evidence of measurable
- •3.Subjects must show evidence of disease progression by radiologic image techniques within 12 months prior to signing informed consent, according to RECIST 1.1 (Appendix I).
- •4.Subjects must meet the following inclusion criterion regarding primary tumor site:
- •a)Pancreatic origin:
- •b)Gastrointestinal origin:
- •5. Only for patients with pancreatic origin neuroendocrine tumors, one previous line with chemotherapy is allowed.
- •6.Concomitant somatostatin analogues are allowed in both cohorts during the study.
- •7.Patients with known brain metastases who have completed whole brain radiotherapy, stereotactic radiosurgery or complete surgical resection, will be eligible if they have remained clinically stable, asymptomatic and off of steroids for at least one month.
- •8.All prior chemotherapy or radiation-related toxicities must have resolved to < Grade 2 (following CTCAE V 4.03 grade levels), except alopecia and infertility.
- •9.Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 ? 1 (Appendix II).
- •10.Previous liver locoregional therapies, such as (chemo) embolization, radiofrequency or liver-directed radioembolization, or systemic peptide-receptor radionucleotide therapy are allowed if the procedure was performed at least 6 months previous the informed consent form signature.
- •11.Adequately controlled blood pressure with or without antihypertensive medications, defined as BP < 150/90 mmHg at screening and no change in antihypertensive medications within 1 week prior to the Screening Visit.
- •12.Adequate renal function defined as calculated creatinine clearance ? 30 mL/min per the Cockcroft and Gault formula (Appendix III).
- •13.Adequate bone marrow function
- •14.Adequate blood coagulation function.
- •15.Adequate liver function:
- •16.Males or females age ? 18 years at the time of informed consent.
- •17. All females must have a negative serum or urine pregnancy test Females of childbearing potential must agree to use a medically acceptable method of
- •18.Male subjects who are partners of women of childbearing potential must use or their partners must use a highly effective method of contraception
- •19.Voluntary provision of written informed consent and the willingness and ability to comply with all aspects of the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 110
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 110
排除标准
- •Subjects who meet any of the following criteria will be excluded from this study:
- •1.WHO Classification G3 neuroendocrine tumors of the pancreas and gastrointestinal tract.
- •2.Two or more prior lines of targeted agents-based therapy in pancreatic origin and any previous line of targeted therapy for gastrointestinal origin or any ongoing antiproliferative treatment for advanced/metastatic neuroendocrine tumors, with the exception of somatostatin analogues therapy.
- •3.More than one previous line of chemotherapy in pancreatic neuroendocrine tumors.
- •4.Previous chemotherapy in gastrointestinal neuroendocrine tumors.
- •5.Prior treatment with lenvatinib.
- •6.Subjects who have received any anti-cancer treatment within 21 days or any investigational agent within 30 days prior to the first dose of study drug and should have recovered from any toxicity related to previous anti-cancer treatment. This does not apply to the use of somatostatin analogues for symptomatic therapy.
- •7.Major surgery within 3 weeks prior to the first dose of study drug.
- •8.Subjects having > 1+ proteinuria on urine dipstick testing will undergo 24h urine collection for quantitative assessment of proteinuria. Subjects with urine protein ? 1 g/24h will be ineligible.
- •9.Gastrointestinal malabsorption, or any other condition in the opinion of the investigator that might affect the absorption of lenvatinib.
- •10.Significant cardiovascular impairment.
- •11.Prolongation of QTcF interval to > 480 msec.
- •12.Bleeding or thrombotic disorders or use of anticoagulants, such as warfarin, or similar agents requiring therapeutic international normalized ration (INR) monitoring. Treatment with low molecular weight heparin (LMWH) is allowed.
- •13.Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug.
- •14.Active infection (any infection requiring treatment).
- •15.Active malignancy within the past 5 years.
- •16.Known intolerance to any of the study drugs (or any of the excipients).
- •17.Any medical or other condition which, in the opinion of the investigator, would preclude participation in a clinical trial.
- •18.Females who are pregnant or breastfeeding.
- •19.Documented active alcohol or drug abuse.
- •20.Patients with a prior history of non-compliance with medical regimens.
研究者
相似试验
进行中（未招募）
2 期
A study to test a new type of treatment for blood cancer. In this new treatment the blood cells ofpatients are modified to kill cancer cell on their own.CTRI/2022/03/041162Immuneel Therapeutics Private Limited
进行中（未招募）
不适用
A phase II study to assess the efficacy and safety of frontline combination of dasatinib (SPRYCEL®) and pegylated-interferon alpha 2b (Peg-IFNa2b) therapy in patients newly diagnosed with chronic phase chronic myeloid leukaemia (CP-CML) - DASA-PEGIFPatients with newly diagnosed chronic phase Chronic Myeloid Leukemia (CP-CML), not previously treated with Tyrosine Kinase Inhibitors (TKIs). First line therapy.MedDRA version: 14.1Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000004864EUCTR2012-003389-42-FRCHU DE POITIERS
进行中（未招募）
1 期
A study to evaluate the safety and efficacy of Lerociclib in participants with advanced breast cancer.MedDRA version: 20.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10006289Term: Benign and malignant breast neoplasmsSystem Organ Class: 100000004872MedDRA version: 20.0Level: HLTClassification code 10006290Term: Breast and nipple neoplasms malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Metastatic breast cancerEUCTR2021-005238-40-ITEQRx International, Inc.100
进行中（未招募）
1 期
A study to investigate whether adding a new hormone treatment for breast cancer, called Irosustat, to current hormone treatment (aromatase inhibitor) can affect the growth of breast cancer.EUCTR2011-005680-25-GBImperial College London28
进行中（未招募）
不适用
A Phase II study to evaluate the efficacy, safety and pharmacodynamics of lapatinib in combination with paclitaxel as neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer - Lapatinib combined with paclitaxel in newly diagnosed inflammatory breast cancer (IBC)ewly diagnosed infammatory breast cancer (IBC)EUCTR2004-001905-93-GBGlaxoSmithKline R&D Ltd60